PNT - Why Is Cancer Treatment Focused POINT Biopharma Stock Trading Higher Today? | Benzinga
Eli Lilly And Co (NYSE: LLY) agreed to acquire POINT Biopharma Global Inc (NASDAQ: PNT) at $12.50 per share in cash, an aggregate of approximately $1.4 billion.
POINT Biopharma is a radiopharmaceutical company with a pipeline of clinical and preclinical-stage radioligand therapies in development for cancer.
Radioligand therapy can precisely target cancer by linking a radioisotope to a targeting molecule that delivers radiation directly to ...